Multiple Myeloma — Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Citation(s)
A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy